In postmenopausal women with osteoporosis, denosumab significantly improved trabecular bone score (TBS), an index of trabecular microarchitecture

Michael R. McClung(Bone Health and Osteoporosis Foundation), Cesar Libanati(Amgen (United States)), José Zanchetta(Universidad del Salvador), H. Didier, A. Wang, Maria Luisa Brandi(Vita-Salute San Raffaele University), Kurt Lippuner(University of Bern), Jiwon Yun(Korea University Medical Center), JM Kaufman, Carol Zapalowski, R. Chapurlat, Henry G. Bone(University of Arizona)
IRIS
January 1, 2012
Cited by 6

Related Papers

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
|Journal of Bone and Mineral Research|2008|508
Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial
|Arthritis & Rheumatism|2009|497